Integra LifeSciences Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Integra LifeSciences Holdings şirketinin toplam hissedar öz sermayesi $1.5B ve toplam borcu $1.8B olup, bu da borç-öz sermaye oranını 118.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $4.1B ve $2.5B dir. Integra LifeSciences Holdings 'in FAVÖK'ü $193.9M faiz karşılama oranı 4.2 dur. Şirketin $277.6M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

118.9%

Borç/özkaynak oranı

US$1.81b

Borç

Faiz karşılama oranı	4.2x
Nakit	US$277.60m
Eşitlik	US$1.52b
Toplam yükümlülükler	US$2.54b
Toplam varlıklar	US$4.07b

Son finansal sağlık güncellemeleri

Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?

Aug 21

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Feb 11

Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Nov 06

These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Apr 07

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Jan 05

Recent updates

There's No Escaping Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Muted Revenues Despite A 42% Share Price Rise

Nov 05

Is Now The Time To Look At Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Oct 24

Why Investors Shouldn't Be Surprised By Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Low P/S

Sep 08

Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?

Aug 21

At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?

Jul 01

Integra LifeSciences Still Underperforming As Manufacturing Issues Linger

Jun 21

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price

May 28

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

Feb 27

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Feb 11

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jan 14

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Dec 31

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Dec 03

Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Nov 06

Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Oct 24

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Sep 22

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Aug 15

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Jul 03

Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jun 19

Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

May 05

These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Apr 07

Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital

Mar 26

At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?

Mar 14

Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?

Feb 27

Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Feb 02

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Jan 05

Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return

Dec 21

When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Dec 08

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: IART 'nin kısa vadeli varlıkları ( $1.1B ) kısa vadeli yükümlülüklerini ( $912.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: IART 'un kısa vadeli varlıkları ( $1.1B ) uzun vadeli yükümlülüklerini ( $1.6B ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: IART 'nin net borç/öz sermaye oranı ( 100.6% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: IART şirketinin borç/öz sermaye oranı son 5 yılda 107.3% seviyesinden 118.9% seviyesine yükseldi.

Borç Kapsamı: IART 'nin borcu işletme nakit akışı ( 7.6% ) tarafından iyi bir şekilde karşılanmıyor.

Faiz Kapsamı: IART 'in borcuna ilişkin faiz ödemeleri EBIT ( 4.2 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Integra LifeSciences Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Recent updates

Integra Lifesciences Holdings Corporation Provides Earnings Guidance for the Fourth Quarter and Updates Earnings Guidance for the Full Year of 2024

There's No Escaping Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Muted Revenues Despite A 42% Share Price Rise

Integra LifeSciences Holdings Corporation Announces Chief Executive Officer Changes

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.052 profit in 2Q 2023)

Investor sentiment improves as stock rises 25%

Is Now The Time To Look At Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Why Investors Shouldn't Be Surprised By Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Low P/S

Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?

Consensus EPS estimates fall by 89%

Price target decreased by 18% to US$28.20

Integra LifeSciences Holdings Corporation Provides Earnings Guidance for the Third Quarter and Updates Earnings Guidance for the Full Year of 2024

Investor sentiment deteriorates as stock falls 19%

Integra LifeSciences Holdings Corporation to Report Q2, 2024 Results on Jul 29, 2024

Integra LifeSciences Holdings Corporation(NasdaqGS:IART) dropped from Russell 1000 Dynamic Index

At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?

Integra LifeSciences Still Underperforming As Manufacturing Issues Linger

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price

Independent Presiding Director recently bought US$996k worth of stock

Consensus EPS estimates fall by 19%, revenue upgraded

Integra LifeSciences Holdings Corporation Provides Revenue Guidance for the Second Quarter and Full Year 2024

Price target decreased by 21% to US$35.20

Full year 2023 earnings released: EPS: US$0.85 (vs US$2.18 in FY 2022)

Investor sentiment deteriorates as stock falls 21%

Integra LifeSciences Holdings Corporation (NasdaqGS:IART) acquired 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million.

Integra LifeSciences Holdings Corporation, Annual General Meeting, May 09, 2024

Integra Lifesciences Launches Micromatrix Flex to Provide Convenient Access to Hard-To-Reach Areas in Complex Cases

Insider notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 17%

Consensus EPS estimates fall by 31%

Integra LifeSciences Holdings Corporation Announces Board Changes

Full year 2023 earnings: EPS misses analyst expectations

Integra Lifesciences Holdings Corporation Provides Earnings Guidance for the First Quarter and for the Full Year 2024

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Integra LifeSciences Holdings Corporation to Report Q4, 2023 Results on Feb 28, 2024

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Integra LifeSciences Holdings Corporation (NasdaqGS:IART) entered into a definitive agreement to acquire 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million.

Integra LifeSciences Holdings Corporation (NasdaqGS:IART) entered into a definitive agreement to acquire 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million.

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Profit margin trend

Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Levi & Korsinsky Notifies Integra Lifesciences Holdings Corporation Investors of a Class Action Lawsuit and Upcoming Deadline

Integra LifeSciences Holdings Corporation to Report Q3, 2023 Results on Oct 25, 2023

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Integra Lifesciences Holdings Corporation

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Consensus EPS estimates fall by 17%

New minor risk - Earnings quality

Integra LifeSciences Holdings Corporation (NasdaqGS:IART) announces an Equity Buyback for $225 million worth of its shares.

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Integra LifeSciences Holdings Corporation to Report Q2, 2023 Results on Jul 27, 2023

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Integra LifeSciences Holding Corporation Announces Complete Enrollment in DuraSorb Monofilament Mesh U.S. IDE Study

Integra Lifesciences Holdings Corporation Appoints Lea Daniels Knight as Executive Vice President, Effective June 28, 2023

Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

President recently bought US$300k worth of stock

Consensus EPS estimates fall by 22%

Price target decreased by 11% to US$51.33

Now 32% undervalued after recent price drop

Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital

At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?

Insider recently sold US$100k worth of stock

Insider recently sold US$215k worth of stock

Consensus EPS estimates fall by 10%